secwatch.observer — SEC 8-K summary
======================================

Issuer:     CAPRICOR THERAPEUTICS, INC. (CAPR)
CIK:        0001133869
Form:       8-K
Filed at:   2022-08-10T23:59:59+00:00
Accession:  0001558370-22-013054
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Capricor Q2 net loss $7.1M; CAP-1002 Phase 3 trial underway, cash $51.4M
------------------------------------------------------------------------

- Net loss $7.1M ($0.29/share) vs $4.7M ($0.21/share) in Q2 2021.
- Cash & equivalents $51.4M at June 30, 2022, up from $34.9M at Dec. 31, 2021.
- First patient dosed in HOPE-3 pivotal Phase 3 trial of CAP-1002 for late-stage Duchenne muscular dystrophy.
- Positive one-year HOPE-2 OLE data showed statistically significant skeletal muscle improvement (PUL v2.0, p=0.02).
- Requesting FDA meeting to discuss CAP-1002 approval pathway; cash runway into Q2 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1133869/000155837022013054/0001558370-22-013054-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1133869/000155837022013054/capr-20220810x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-22-013054

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer